Fig. 4: BinJ/JEVNSW/22-prME vaccination and immunogenicity studies. | npj Vaccines

Fig. 4: BinJ/JEVNSW/22-prME vaccination and immunogenicity studies.

From: A chimeric vaccine derived from Australian genotype IV Japanese encephalitis virus protects mice from lethal challenge

Fig. 4

a Timeline for BinJ/JEVNSW/22-prME vaccinations and immunogenicity studies. Serum taken 16 weeks post-vaccination was assessed in immunogenicity studies. b Total Ig response to each of the 5 JEV genotypes. c Total Ig response to each of the 5 JEV genotypes. Plotted mid-point titres (t50) from data displayed in (b). d Neutralising antibody titres against WT GII (Fu), GIII (Nakayama; SA-14) and GIV (NSW/22). mAb BJ-6E6 was used as a control to ensure sufficient antigen was present. NS not significant.

Back to article page